###begin article-title 0
###xml 32 34 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 115 120 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</sup>
###xml 136 137 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 89 93 <span type="species:ncbi:10116">rats</span>
Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nalpha-Bodipy]-des-Arg9-bradykinin
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 11 13 11 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 403 404 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 313 317 <span type="species:ncbi:10116">rats</span>
The kinin B1 receptor (B1R) is upregulated by pro-inflammatory cytokines, bacterial endotoxins and hyperglycaemia-induced oxidative stress. In animal models of diabetes, it contributes to pain polyneuropathy. This study aims at defining the cellular localization of B1R in thoracic spinal cord of type 1 diabetic rats by confocal microscopy with the use of a fluorescent agonist, [Nalpha-Bodipy]-des-Arg9-BK (BdABK) and selective antibodies.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 177 178 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 254 255 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 258 261 258 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 274 276 274 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 289 290 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 293 296 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 329 337 329 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
Diabetes was induced by streptozotocin (STZ; 65 mg/kg, i.p.). Four days post-STZ treatment, B1R expression was confirmed by quantitative real-time PCR and autoradiography. The B1R selectivity of BdABK was determined by assessing its ability to displace B1R [125I]-HPP-desArg10-Hoe140 and B2R [125I]-HPP-Hoe 140 radioligands. The in vivo activity of BdABK was also evaluated on thermal hyperalgesia.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 169 170 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 203 204 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 221 224 221 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 252 255 252 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 266 267 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 301 302 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 394 395 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 494 495 494 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 108 112 <span type="species:ncbi:10116">rats</span>
###xml 459 463 <span type="species:ncbi:10116">rats</span>
###xml 483 487 <span type="species:ncbi:10116">rats</span>
###xml 633 637 <span type="species:ncbi:10116">rats</span>
B1R was increased by 18-fold (mRNA) and 2.7-fold (binding sites) in the thoracic spinal cord of STZ-treated rats when compared to control. BdABK failed to displace the B2R radioligand but displaced the B1R radioligand (IC50 = 5.3 nM). In comparison, IC50 values of B1R selective antagonist R-715 and B1R agonist des-Arg9-BK were 4.3 nM and 19 nM, respectively. Intraperitoneal BdABK and des-Arg9-BK elicited dose-dependent thermal hyperalgesia in STZ-treated rats but not in control rats. The B1R fluorescent agonist was co-localized with immunomarkers of microglia, astrocytes and sensory C fibers in the spinal cord of STZ-treated rats.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 101 105 <span type="species:ncbi:10116">rats</span>
The induction and up-regulation of B1R in glial and sensory cells of the spinal cord in STZ-diabetic rats reinforce the idea that kinin B1R is an important target for drug development in pain processes.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 134 136 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 141 143 141 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 155 156 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 310 311 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 359 360 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 379 380 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 588 589 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Kinins are vasoactive peptides and central mediators acting through the activation of two G-protein-coupled receptors (R) denoted as B1 and B2 [1,2]. The B2R is widely and constitutively expressed in central and peripheral tissues and is activated by its preferential agonists bradykinin (BK) and Lys-BK. The B1R is activated by the active metabolites des-Arg9-BK and Lys-des-Arg9-BK and has a low level of expression in healthy tissues. The latter receptor is upregulated after exposure to pro-inflammatory cytokines, bacterial endotoxins, and hyperglycaemia-induced oxidative stress [3-7].
###end p 11
###begin p 12
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 193 194 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 636 637 636 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10116">rats</span>
An important role for kinin B1R has been postulated in nociception and pain [8-10]. B1R knock out mice are less sensitive to pro-inflammatory pain stimuli and to spinal sensitization [11-13]. B1R partakes to mechanical and/or thermal hyperalgesia induced by cytokines [14,15] through peripheral protein kinase C activation [16] and in the formalin test [17,18]. It also contributes to neuropathic pain after peripheral nerve injury [18-23] or after the induction of type 1 diabetes with streptozotocin (STZ) [24-27] and type 2 diabetes with high glucose feeding [7,28,29]. Thermal hyperalgesia was evoked by intraspinal stimulation of B1R in STZ-diabetic rats [9].
###end p 12
###begin p 13
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 190 191 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 383 384 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 44 47 <span type="species:ncbi:10116">rat</span>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 96 99 <span type="species:ncbi:10116">rat</span>
Basal expression of B1R was reported in the rat and human spinal cord dorsal horn as well as in rat dorsal root ganglion and small caliber primary sensory neurons [30-32]. Autoradiographic B1R binding sites are increased and distributed all over the grey matter of the spinal cord after peripheral nerve injury [22] and in models of diabetes [7,29,33]. This spatial distribution of B1R binding sites suggests that this receptor is not limited to primary sensory afferents but could also be present on spinal cord microglia and astrocytes.
###end p 13
###begin p 14
###xml 28 29 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 133 134 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 208 209 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 227 228 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 304 305 300 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 309 312 305 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 325 327 321 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 342 343 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 347 350 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 460 461 456 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 559 567 555 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 767 768 763 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 875 876 871 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1069 1070 1065 1066 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1163 1164 1159 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1165 1167 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 679 683 <span type="species:ncbi:10116">rats</span>
###xml 832 836 <span type="species:ncbi:10116">rats</span>
###xml 913 917 <span type="species:ncbi:10116">rats</span>
To consolidate the role of B1R in pain polyneuropathy, its cellular distribution was investigated in the spinal cord of STZ-induced B1R with a newly developed fluorescent agonist named [Nalpha-Bodipy]-des-Arg9-BK (BdABK). The B1R selectivity of BdABK was determined by assessing its ability to displace B1R ([125I]-HPP-desArg10-Hoe 140) and B2R ([125I]-HPP-Hoe 140) radioligands by autoradiography. Moreover, the displacement of BdABK fluorescent labeling by B1R antagonists (R-715 and SSR240612) was assessed by confocal microscopy. We also investigated the in vivo activity of BdABK in comparison with its native agonist on thermal hyperalgesia in both STZ-treated and control rats. Appropriate selective antibodies were used in confocal microscopy to co-localize B1R on astrocytes, microglia and sensory C fibers in STZ-diabetic rats. The induction and overexpression of B1R in the spinal cord of STZ-diabetic rats was confirmed by qPCR and autoradiography. Experiments were achieved 4 days after STZ administration because previous studies showed that spinal cord B1R was maximally up-regulated and engaged in thermal hyperalgesia 2 days after STZ treatment [9,33].
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Animals and treatments
###end title 16
###begin p 17
###xml 250 269 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
All research procedures and the care of the animals were in compliance with the guiding principles for animal experimentation as enunciated by the Canadian Council on Animal Care and were approved by the Animal Care Committee of our University. Male Sprague-Dawley rats (200-225 g, Charles River, St-Constant, Que., Canada) were housed two per cage, under controlled conditions of temperature (23degreesC) and humidity (50%), on a 12 h light-dark cycle and allowed free access to normal chow diet (Charles River Rodent) and tap water.
###end p 17
###begin title 18
STZ treatment
###end title 18
###begin p 19
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 511 515 <span type="species:ncbi:10116">rats</span>
Rats were used 5 days after their arrival and injected under low light with freshly prepared STZ (65 mg/kg; i.p.; Sigma-Aldrich, Oakville, ON, Canada). Age-matched controls were injected with vehicle (sterile saline 0.9%, pH. 7.0) [33]. Glucose concentrations were measured, with a commercial blood glucose-monitoring kit (Accusoft; Roche Diagnostics, Laval, Que., Canada), in blood samples obtained from the tail vein, in non-fasting animals, before STZ injection, and 4 days after treatment. Only STZ-treated rats whose blood glucose concentration was higher than 20 mM were considered as diabetic.
###end p 19
###begin title 20
###xml 15 20 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</sup>
###xml 36 37 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
Synthesis of [Nalpha-Bodipy]-des-Arg9-BK
###end title 20
###begin p 21
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s</italic>
###xml 128 132 128 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 223 224 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 287 288 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 323 325 321 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 400 404 398 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 700 702 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 703 705 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
BdABK was synthesized using 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionic acid succinimidyl ester (BODIPY(R) FL SE, Molecular Probes/Invitrogen Canada Inc, Burlington, ON; emission 510 nm) and des-Arg9-BK (Bachem Bioscience inc., King of Prussia, PA, USA). Des-Arg9-BK was solubilized in 100 mM NaHCO3 0.1 M (pH 8.4), at a concentration of 1 mg/ml and two equivalents of BODIPY(R) FL SE, solubilized in degassed dimethyl sulfoxide, at a concentration of 5 mg/ml was added. Completion of the reaction was achieved in 2 h, at ambient temperature, under continuous agitation. The fluorescent peptide was lyophilized and purified by C18 reverse-phase HPLC as previously described [34,35]. The purity of the peptide was >/= 98% as assessed by analytical HPLC (UV and fluorescence detection).
###end p 21
###begin title 22
Tissue preparation for autoradiography and microscopy
###end title 22
###begin p 23
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 34 38 <span type="species:ncbi:10116">rats</span>
Four days after injection of STZ, rats were anaesthetized with CO2 inhalation and then decapitated. Upper thoracic spinal cord (T3-T7) was removed and frozen in 2-methylbutane (cooled at -40degreesC following exposure to liquid nitrogen) and stored at -80degreesC. Few days later, spinal cords were mounted in a gelatin block and serially cut into 20-mum thick coronal sections with a cryostat. Thus the sections were thaw-mounted on 0.2% gelatin-0.033% chromium potassium sulfate-coated slides and kept at -80degreesC for 1 month to allow the adhesion of sections to the coverslip glasses.
###end p 23
###begin title 24
Confocal microscopy
###end title 24
###begin title 25
Slides preparation
###end title 25
###begin p 26
###xml 161 162 161 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 394 396 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
On the day of experiments, sections were thawed at room temperature for 10 min to enhance sections adhesion. They were pre-incubated for 10 min in 25 mM PIPES-NH4OH buffer (pH 7.4) to allow degradation of endogenous kinins which could occupy receptors. Sections were exposed for 90 min to 50 muM BdABK. Thereafter, slides were washed twice (1 min) in PIPES and fixed with 4% para-formaldehyde [36]. Slides were washed three times (5 min) and then exposed to 1 M of glycine for 90 min to eliminate autofluorescence from aldehyde-fixed tissue. Tissues were permeabilized for 45 min with 0.1% Triton X-100.
###end p 26
###begin title 27
Immunolabeling protocol
###end title 27
###begin p 28
###xml 460 462 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 463 465 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 620 622 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 768 770 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 956 958 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 86 92 <span type="species:ncbi:9913">bovine</span>
###xml 120 126 <span type="species:ncbi:9793">donkey</span>
###xml 312 318 <span type="species:ncbi:9986">Rabbit</span>
###xml 468 475 <span type="species:ncbi:9031">Chicken</span>
###xml 625 631 <span type="species:ncbi:9986">Rabbit</span>
###xml 773 778 <span type="species:ncbi:10090">Mouse</span>
###xml 1002 1007 <span type="species:ncbi:10090">mouse</span>
###xml 1047 1054 <span type="species:ncbi:9031">chicken</span>
###xml 1103 1109 <span type="species:ncbi:9986">rabbit</span>
Slides were incubated with a blocking buffer (25 mM PIPES buffer supplemented with 3% bovine serum albumin (BSA) and 3% donkey serum) to prevent non-specific labeling. Antibodies were diluted in blocking buffer. A direct marker of DNA (TOPRO-3; Molecular Probes, Eugene, OR) was used at concentration of 1:5000. Rabbit anti-Ionized calcium binding adapter molecule 1 (anti-IBA-1, Wako, Richmond, VA) at a concentration of 2 mug/ml was used to label microglia [37-39]. Chicken anti-Glial fibrillary acidic protein (anti-GFAP, Chemicon, Hornby, ON) at a concentration of 1:500 was used as a specific marker of astrocytes [40]. Rabbit anti-calcitonin-gene-related peptide (CGRP) (Chemicon, Hornby, ON) at a concentration of 1:2000 was used as marker of sensory C fibers [41]. Mouse anti-transient receptor potential vanilloid 1 (TRPV1) (Chemicon, Hornby, ON) at a concentration of 1 mug/ml was used to label capsaicin receptor expressed on primary afferents [42]. Secondary antibodies were rhodamine anti-mouse (Chemicon, Hornby, ON) 1:500; cy5 anti-chicken (Chemicon, Hornby, ON) 1:500 and rhodamine anti-rabbit (Chemicon, Hornby, ON) 1:500.
###end p 28
###begin title 29
Coverslip and microscopy
###end title 29
###begin p 30
Slides were washed 3 times (5 min), mounted with coverslip, fixed with mowiol (12 h at room temperature) and stored at -4degreesC for 1 month or used in confocal microscopy.
###end p 30
###begin title 31
SYBR green-based quantitative RT-PCR
###end title 31
###begin p 32
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">later </italic>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 879 880 879 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 889 890 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 34 38 <span type="species:ncbi:10116">rats</span>
###xml 777 780 <span type="species:ncbi:10116">rat</span>
Four days after injection of STZ, rats were anaesthetized with CO2 inhalation and then decapitated. The thoracic spinal cord (T1-T2) was isolated and approximately 10 mg of tissue were put in RNA later stabilization reagent (QIAGEN, Valencia, CA, USA). Total RNA was extracted from tissue according to the manufacturer's instructions. First-strand cDNA synthesized from 400 ng total RNA with random hexamer primers was used as template for each reaction with the QuantiTect Rev Transcription Kit (QIAGEN). SYBR Green-based real-time quantitative PCR using Mx3000p device for signal detection (Stratagene, La Jolla, CA, USA) was performed as described [43]. PCR was performed in SYBR Green Master mix (QIAGEN) with 300 nM of each primer. For standardization and quantification, rat 18S was amplified simultaneously. The primer pairs were designed by Vector NTI software and used [6] (Table 1).
###end p 32
###begin p 33
PCR primer pairs used in this study
###end p 33
###begin p 34
###xml 273 275 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 346 360 322 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct </sup>
###xml 368 370 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
PCR conditions were as follows: 95degreesC for 15 min, followed by 46 cycles at 94degreesC for 15 s, 60degreesC for 30 s and 72degreesC for 30 s. The cycle threshold (Ct) value represents the cycle number at which a fluorescent signal rises statistically above background [44]. The relative quantification of gene expression was analyzed by the 2-DeltaDeltaCt method [45].
###end p 34
###begin title 35
Quantitative autoradiography
###end title 35
###begin title 36
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 43 45 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
Specific binding sites of [125I]-HPP-desArg10-Hoe 140 and [125I]-HPP-Hoe 140
###end title 36
###begin p 37
###xml 28 29 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 96 98 96 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">0 </sup>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 198 200 198 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">0 </sup>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 524 525 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 742 745 742 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 758 760 758 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 773 776 773 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 926 927 925 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 964 965 960 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 970 971 966 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 979 980 975 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 986 987 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1015 1016 1010 1011 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1089 1091 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1384 1388 1358 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1476 1479 1448 1451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 1766 1769 1729 1732 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 1861 1863 1824 1826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 645 651 <span type="species:ncbi:9913">bovine</span>
The radioligands for kinin B1R, HPP-desArg10-Hoe140 (3-(4 hydroxyphenyl) propionyl-desArg9-D-Arg0 [Hyp3, Thi5, D-Tic7, Oic8]Bradykinin) and kinin B2R, HPP-Hoe140 (3-(4 hydroxyphenyl) propionyl-D-Arg0 [Hyp3, Thi5, D-Tic7, Oic8]Bradykinin) were synthesized and kindly provided by Dr Witold Neugebauer (Dept Pharmacology, University of Sherbrooke, Sherbrooke, Que., Canada). They were iodinated by the chloramine T method [46]. On the day of experiments, sections were incubated at room temperature for 90 min in 25 mM PIPES-NH4OH buffer (pH 7.4) containing: 1 mM 1,10-phenanthroline, 1 mM dithiothreitol, 0.014% bacitracin, 0.1 mM captopril, 0.2% bovine serum albumin (protease free) and 7.5 mM magnesium chloride in the presence of 200 pM of [125I]-HPP-desArg10-Hoe 140 or [125I]-HPP-Hoe 140 (specific activity: 2000 cpm/fmol or 1212 Ci/mmol) [29,33]. Non-specific binding was determined in the presence of 1 muM of unlabeled B1R antagonist: R-715 (AcLys [D-betaNal7, Ile8]des-Arg9-BK) [1] or of 1 muM of unlabeled B2R antagonist: Hoe 140 (Icatibant or JE 049, Jerini AG, Berlin, Germany) [47]. At the end of the incubation period, slides were transferred sequentially through four rinses of 4 min each in 25 mM PIPES (pH 7.4; 4degreesC) dipped for 15s in distilled water (4degreesC) to remove the excess of salts, and then air-dried. Kodak Scientific Imaging Films BIOMAXtrade mark MR(R) (Amersham Pharmacia Biotech Canada) were juxtaposed onto the slides in the presence of [125I]-microscales and exposed at room temperature for 7 days. The films were developed (GBX developer) and fixed (GBX fixer). Autoradiograms were quantified by densitometry using an MCIDtrade mark image analysis system (Imaging Research, St. Catharines, ON, Canada). A standard curve from [125I]-microscales was used to convert density levels into fentomoles per milligram of protein [48]. Specific binding was determined by subtracting values of nonspecific binding from that of total binding.
###end p 37
###begin title 38
Specificity of BdABK
###end title 38
###begin p 39
###xml 40 41 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 138 140 138 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 183 187 183 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 192 195 192 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 219 220 219 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 325 326 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 348 349 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 490 493 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 542 546 542 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 551 554 551 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 580 581 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 934 937 934 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 1233 1235 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 673 676 <span type="species:ncbi:10116">rat</span>
###xml 694 698 <span type="species:ncbi:10116">rats</span>
To assess the specificity of BdABK for B1R, competition curves were performed in autoradiography by incubating 200 pM of [125I]-HPP-desArg10-Hoe 140 with increasing concentrations (10-10 to 10-6 M) of R-715 (selective B1R antagonist, kindly provided by Dr Domenico Regoli, Pharmacology, University of Ferrara, Italy), des-Arg9-BK (dABK, selective B1R agonist, Bachem Bioscience inc., King of Prussia, PA, USA) and BdABK. Moreover, competition curves were performed by incubating 200 pM of [125I]-HPP-Hoe 140 with increasing concentrations (10-10 to 10-6 M) of Hoe 140 (selective B2R antagonist) and BdABK. Each concentration of each competitor was tested on 4 sections per rat from 7 different rats. Those sections were exposed to the film, and total binding was calculated as described above. Moreover, the specificity of BdABK was determined in confocal microscopy by the displacement of fluorescent labeling with the addition of 10-5 M R-715 or SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4- [2R, 6S)-2,6 dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-ethylpropanamide hydrochloride] (kindly provided by Dr Pierre Carayon, Sanofi-Aventis, Montpellier, France) [18] to the incubation medium.
###end p 39
###begin title 40
Microglial cell culture
###end title 40
###begin title 41
Primary cell culture method
###end title 41
###begin p 42
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1052 1054 1039 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1208 1210 1188 1190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 182 200 <span type="species:ncbi:10116">Sprague-Dawley rat</span>
Mixed glial cultures were prepared following the protocol of McCarthy and de Vellis [49] with some modifications. Briefly, forebrains were dissected out from one litter of 2-day-old Sprague-Dawley rat pups and the meninges were stripped off before enzymatic and mechanical dissociation. For enzymatic dissociation, HBSS containing 0.25% trypsin (Gibco 15090-046) was used. The tissue-trypsin suspension was incubated for 20 min at 37degreesC in a water bath with intermittent shaking. After the waiting time for the trypsin digestion is over we added to the tissue-trypsin suspension a mixture of prewarmed DMEM/Dnase I (Sigma DN-25, Dnase I final concentration 0. 25 mg/ml) followed by an incubation for 4 min at 37degreesC. The resulting suspension was dispersed by a mild mechanical trituration which consisted in the passage through 18-, 22- and 25- gauge needles. This cell suspension was then filtred through 70 mum strainer (BD Falcon 352350). After extensive washs in prewarmed HBSS, these dissociated cells were resuspended and plated in 75-cm2 Falcon tissue-culture flasks (BD Biosciences) previously coated with 10 mug/ml poly-D-lysine (PDL). These mixed cells were growing at 37degreesC and 5% CO2 in DMEM (Gibco) supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 mg/ml). The media was changed every 2 or 3 days thereafter.
###end p 42
###begin p 43
###xml 11 19 11 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-vitro</italic>
###xml 278 279 272 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 615 616 603 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
At 10 days-in-vitro, a confluent monolayer of astrocytes was apparent, on top of which oligodendrocyte precursor cells and a loosely attached layer of phase-bright microglia was obtained. Microglias were collected by shaking the flasks for 1 h at 200 rpm at 37degreesC and 5% CO2. Dislodged cells were resuspended and grown in culture medium for microglia [RPMI medium 1640 (Gibco) supplemented with 10% FBS, L-glutamine (1 mM), sodium pyruvate (1 mM), penicillin (100 units/ml), and streptomycin (100 mg/ml)]. The cells were allowed to adhere to the surface of PDL-coated coverslips (30 min at 37degreesC and 5% CO2), and nonadherent cells were rinsed off.
###end p 43
###begin title 44
Microglia cells preparation for confocal microscopy
###end title 44
###begin p 45
###xml 74 75 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
Briefly, confluent cells were exposed to 300 nM of BK for 24 h to induce B1R [50,51]. Control cells were exposed to vehicle. After incubation with BdABK, cell were washed, then fixed and permeabilized with 100% methanol previously stored at -20degreesC. The fixed cells were then processed as described for immunostaining.
###end p 45
###begin title 46
Thermal hyperalgesia
###end title 46
###begin p 47
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 844 845 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1003 1004 997 998 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1047 1048 1040 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1090 1091 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1297 1305 1288 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1547 1548 1538 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 135 139 <span type="species:ncbi:10116">rats</span>
###xml 792 796 <span type="species:ncbi:10116">rats</span>
###xml 1248 1252 <span type="species:ncbi:10116">rats</span>
Thermal hyperalgesia was assessed according to the method described by Hargreaves et al., 1988 [52] with minor modifications. Briefly, rats were placed (unrestrained) within a Plexiglass enclosure on a transparent glass floor and allowed to acclimatize for 20-30 min. An infrared beam that constitutes the noxious heat stimulus (Plantar test, Ugo Basile, Italy) was moved beneath the plantar surface of the hind paw. Thermal nociceptive threshold was defined as the latency (seconds) between the heat stimulus (46degreesC) onset and the paw withdrawal using a feedback-controlled shut-down unit. A cut-off time of 33 s was used to avoid tissue damage. Each paw was tested three times alternatively at minimum intervals of 3 min between stimulation to avoid sensitization of the hind paw. The rats were trained on several days prior to testing B1R agonists. Thereafter, the thermal nociceptive threshold was assessed on 3 consecutive days as follows: day 1: baseline, saline and the first dose of des-Arg9-BK and BdABK (22.5 mug/kg); day 2: des-Arg9-BK and BdABK (225 mug/kg); day 3: des-Arg9-BK and BdABK (2250 mug/kg). Agonists were injected intraperitoneally at 1 h apart. This series of experiments was conducted in 3 control and 3 STZ-diabetic rats because the quantity of BdABK available for in vivo study was restricted. Thermal hyperalgesia was calculated as a percentage of the maximum possible effect (% MPE) according to the following formula: % MPE = (100 x (drug latency minus baseline latency)/(cut-off time minus baseline latency)) [9]. The baseline latency corresponds to the average of the first three measurements.
###end p 47
###begin title 48
Statistical analyses
###end title 48
###begin p 49
###xml 58 60 56 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 121 122 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 253 256 251 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 60 64 <span type="species:ncbi:10116">rats</span>
All data were expressed as means +/- S.E.M. obtained from n rats. Statistical significance was determined with Student's t-test for unpaired samples or a one-way analysis of variance (ANOVA) followed by post-hoc Dunnett test for multiple comparisons. IC50 values were calculated by Graph Pad Prism 4.0 (GraphPad software, USA). Only probability (P) values less than 0.05 were considered to be statistically significant.
###end p 49
###begin title 50
Results
###end title 50
###begin title 51
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R fluorescent labeling and selectivity of BdABK
###end title 51
###begin p 52
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 491 492 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 550 552 550 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 151 155 <span type="species:ncbi:10116">rats</span>
###xml 322 326 <span type="species:ncbi:10116">rats</span>
Figure 1 illustrates B1R labeling with BdABK from low (i) to high (V) magnification (green dots) in dorsal horn of thoracic spinal cord of STZ-treated rats. As depicted in Figure 2, BdABK showed no labeling in control thoracic spinal cord (A), while the labeling of B1R was apparent in thoracic spinal cord of STZ-treated rats as revealed by green dots (B). Selectivity and specificity of the labeling were demonstrated by the absence of BdABK labeling in STZ-spinal cord sections when the B1R antagonists SSR240612 (D) and R-715 (E) were added at 10-5M.
###end p 52
###begin p 53
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 122 123 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 0 126 0 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B<sub>1</sub>R distribution in thoracic spinal cord of STZ-treated rats was shown by confocal microscopy with [N&#945;-Bodipy]-des-Arg<sup>9</sup>-BK</bold>
###xml 56 60 <span type="species:ncbi:10116">rats</span>
###xml 336 339 <span type="species:ncbi:10116">rat</span>
###xml 370 374 <span type="species:ncbi:10116">rats</span>
B1R distribution in thoracic spinal cord of STZ-treated rats was shown by confocal microscopy with [Nalpha-Bodipy]-des-Arg9-BK. Shown are pictures from low (i) to high magnification (V) of the dorsal horn. Scale bars = 200, 50, 20, 5 and 2.5 mum, respectively from (i) to (V). Pictures are representative of a minimum of 4 sections per rat from 4 different STZ-diabetic rats.
###end p 53
###begin p 54
###xml 23 24 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 53 54 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 92 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">[N&#945;-Bodipy]-des-Arg<sup>9</sup>-BK (BdABK) selectivity for B<sub>1</sub>R was evaluated by confocal microscopy</bold>
###xml 101 102 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 273 274 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 367 369 362 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 390 392 385 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 184 188 <span type="species:ncbi:10116">rats</span>
###xml 576 579 <span type="species:ncbi:10116">rat</span>
###xml 610 614 <span type="species:ncbi:10116">rats</span>
[Nalpha-Bodipy]-des-Arg9-BK (BdABK) selectivity for B1R was evaluated by confocal microscopy. While B1R labeling in the presence of BdABK was absent in thoracic spinal cord of control rats (A), it was shown as green dots in STZ-treated spinal cord (B, and enlarged in C). B1R labeling was absent in STZ-treated spinal cord when BdABK (50 muM) was co-incubated with 10-5M SSR240612 (D) or 10-5M R-715 (E). Background staining represents non specific autofluorescence. Scale bars = 20 mum (A, B, D, E) and 8.2 mum (C). Pictures are representative of a minimum of 4 sections per rat from 4 different STZ-diabetic rats.
###end p 54
###begin title 55
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 9 10 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 26 29 26 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
B1R and B2R binding and IC50 value of BdABK
###end title 55
###begin p 56
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 71 75 71 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 80 83 80 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 209 212 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 225 227 225 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 338 339 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 382 383 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 394 397 394 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 493 497 487 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 502 505 496 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 549 552 543 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 571 572 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 628 629 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 689 690 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 713 715 707 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 279 283 <span type="species:ncbi:10116">rats</span>
###xml 617 621 <span type="species:ncbi:10116">rats</span>
Competition experiments using 200 pM [125I]-HPP-desArg10-Hoe 140 and 10-10 to 10-6 M of des-Arg9-BK, R-715, or BdABK revealed that kinin analogues decreased in a concentration-dependent manner the binding of [125I]-HPP-desArg10-Hoe 140 in the thoracic spinal cord of STZ-treated rats (Fig. 3). The rank order of potency to inhibit total B1R binding sites was R-715 = BdABK > des-Arg9-BK with IC50 values of 4.3 +/- 0.2 nM, 5.3 +/- 0.1 nM and 19 +/- 0.2 nM, respectively. In contrast, BdABK (10-10 to 10-6 M) failed to inhibit the binding of 200 pM [125I]-HPP-Hoe 140 to B2R in the thoracic spinal cord of STZ-treated rats (Fig. 4). In comparison, same concentrations of Hoe 140 displaced B2R binding sites with IC50value of 1.33 +/- 0.1 nM.
###end p 56
###begin p 57
###xml 23 24 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 45 46 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 93 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">[N&#945;-Bodipy]-des-Arg<sup>9</sup>-BK selectivity for B<sub>1</sub>R was evaluated by quantitative autoradiography</bold>
###xml 113 114 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 136 137 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 153 154 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 192 193 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 222 223 214 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 280 284 272 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 289 292 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 324 327 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 340 342 332 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 355 356 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 400 403 <span type="species:ncbi:10116">rat</span>
###xml 421 425 <span type="species:ncbi:10116">rats</span>
[Nalpha-Bodipy]-des-Arg9-BK selectivity for B1R was evaluated by quantitative autoradiography. R-715 (selective B1R antagonist), des-Arg9-BK (selective B1R agonist) and [Nalpha-Bodipy]-des-Arg9-BK (fluorescent agonist of B1R) displaced in a concentration-dependent manner, from 10-10 to 10-6 M, the total binding of 200 pM [125I]-HPP-desArg10-Hoe 140 to B1R. Data are means +/- SEM of 4 sections per rat from 7 different rats for each compound.
###end p 57
###begin p 58
###xml 23 24 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 42 43 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 90 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">[N&#945;-Bodipy]-des-Arg<sup>9</sup>-BK affinity for B<sub>2</sub>R was evaluated by quantitative autoradiography</bold>
###xml 120 124 116 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-10 </sup>
###xml 129 132 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 158 159 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 208 211 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 230 231 226 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 293 294 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 312 313 304 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 346 347 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 403 406 <span type="species:ncbi:10116">rat</span>
###xml 424 428 <span type="species:ncbi:10116">rats</span>
[Nalpha-Bodipy]-des-Arg9-BK affinity for B2R was evaluated by quantitative autoradiography. Increasing concentration (10-10 to 10-6 M) of Hoe 140 (selective B2R antagonist) displaced total binding of 200 pM [125I]-HPP-HOE-140 to B2R. In contrast, same concentrations of [Nalpha-Bodipy]-des-Arg9-BK (fluorescent B1R agonist) did not displace the B2R radioligand. Data are means +/- SEM of 4 sections per rat from 7 different rats for each compound.
###end p 58
###begin title 59
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
BdABK mediated in vivo thermal hyperalgesia
###end title 59
###begin p 60
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 531 532 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 605 606 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 162 166 <span type="species:ncbi:10116">rats</span>
###xml 269 273 <span type="species:ncbi:10116">rats</span>
###xml 337 341 <span type="species:ncbi:10116">rats</span>
The in vivo effect of BdABK on pain behavior was assessed by determining its ability to induce thermal hyperalgesia upon intraperitoneal injection in STZ-treated rats. As expected, BdABK and des-Arg9-BK had no significant effect on the nociceptive threshold in control rats, yet both agonists caused thermal hyperalgesia in STZ-diabetic rats at 0.225 and 2.25 mg/kg. These effects were dose-dependent and significant when compared to saline or control (Fig. 5). BdABK was however slightly but significantly less potent than des-Arg9-BK to induce hyperalgesia at the highest dose. As exemplified by des-Arg9-BK, this response peaked at 15 min post-injection and was reversible after 30 min (Fig. 6).
###end p 60
###begin p 61
###xml 65 66 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 101 102 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 0 176 0 172 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The ability of intraperitoneally injected [N&#945;-Bodipy]-des-Arg<sup>9</sup>-BK and its native agonist, des-Arg<sup>9</sup>-BK, to alter the paw withdrawal threshold in STZ-treated and control rats</bold>
###xml 366 367 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 172 176 <span type="species:ncbi:10116">rats</span>
###xml 289 293 <span type="species:ncbi:10116">rats</span>
The ability of intraperitoneally injected [Nalpha-Bodipy]-des-Arg9-BK and its native agonist, des-Arg9-BK, to alter the paw withdrawal threshold in STZ-treated and control rats. Data represent maximal effects and are the average of 3 readings taken at 9, 12 and 15 min post-injection in 3 rats per group. Statistical comparison to control (*) and 2250 mug/kg des-Arg9-BK (+) are indicated by * + P < 0.05; ** P < 0.01; *** P < 0.001.
###end p 61
###begin p 62
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Time-course effect of des-Arg<sup>9</sup>-BK (2.25 mg/kg, i.p.) on the nociceptive threshold in STZ-treated rats</bold>
###xml 97 101 <span type="species:ncbi:10116">rats</span>
###xml 131 135 <span type="species:ncbi:10116">rats</span>
Time-course effect of des-Arg9-BK (2.25 mg/kg, i.p.) on the nociceptive threshold in STZ-treated rats. Data are means +/- SEM of 3 rats. Statistical comparison to time 0 (*) is indicated by ** P < 0.01.
###end p 62
###begin title 63
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R mRNA expression assessed by qPCR
###end title 63
###begin p 64
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 84 88 <span type="species:ncbi:10116">rats</span>
###xml 188 192 <span type="species:ncbi:10116">rats</span>
A low basal expression of kinin B1R mRNA was detected in the spinal cord of control rats (Fig. 7). This expression was significantly increased (18-fold) in the spinal cord of STZ-diabetic rats.
###end p 64
###begin p 65
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B<sub>1</sub>R mRNA expression in STZ-treated and control thoracic spinal cords was measured by quantitative real-time PCR</bold>
###xml 148 152 <span type="species:ncbi:10116">rats</span>
B1R mRNA expression in STZ-treated and control thoracic spinal cords was measured by quantitative real-time PCR. Data are means +/- SEM of (3 to 6) rats. Statistical comparison with control is indicated by * P < 0.05.
###end p 65
###begin title 66
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Density of B1R binding sites assessed by quantitative autoradiography
###end title 66
###begin p 67
###xml 23 24 23 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 39 48 39 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 104 105 104 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 191 195 <span type="species:ncbi:10116">rats</span>
###xml 316 320 <span type="species:ncbi:10116">rats</span>
###xml 374 378 <span type="species:ncbi:10116">rats</span>
As presented in Figure 8, quantitative in vitro autoradiography showed an increase density of specific B1R binding sites throughout the grey matter of the thoracic spinal cord in STZ-treated rats when compared to age-matched control spinal cord. B1R binding sites (2.4 fmol/mg protein) in spinal cord of STZ-treated rats were 2.7-fold greater than those measured in control rats (0.9 fmol/mg protein).
###end p 67
###begin p 68
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 112 0 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B<sub>1</sub>R binding sites in STZ-treated and control thoracic spinal cords were measured by quantitative autoradiography</bold>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 182 186 <span type="species:ncbi:10116">rats</span>
B1R binding sites in STZ-treated and control thoracic spinal cords were measured by quantitative autoradiography. Specific density of B1R binding sites are means +/- SEM of (7 to 8) rats. Statistical comparison with control is indicated by *** P < 0.001.
###end p 68
###begin title 69
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R colocalized on microglial cells in thoracic spinal cord
###end title 69
###begin p 70
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 115 116 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 172 176 <span type="species:ncbi:10116">rats</span>
Figure 9 shows the colocalization of BdABK, TOPRO-3 and anti-IBA-1 in STZ thoracic spinal cord. Data suggest that B1R is present on spinal microglial cells in STZ-diabetic rats.
###end p 70
###begin p 71
###xml 0 95 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink">STZ-treated thoracic spinal cord was exposed to TOPRO-3, a specific fluorescent dye for DNA (A)</bold>
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 504 507 <span type="species:ncbi:10116">rat</span>
STZ-treated thoracic spinal cord was exposed to TOPRO-3, a specific fluorescent dye for DNA (A). Microglia was identified with anti-IBA-1 (B). The B1R was stained with the selective fluorescent agonist, BdABK (C). Colocalization of the three markers is shown in panel D. TOPRO-3 dye is blue (ext: 642 nm/em: 661 nm), anti-IBA-1 dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 5.38 mum. Pictures presented are representative of a minimum of 4 sections per rat from 4 different animals.
###end p 71
###begin title 72
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R colocalized in primary cultured microglial cells
###end title 72
###begin p 73
###xml 7 9 7 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10</xref>
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 285 286 283 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 303 312 301 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Figure 10 shows the colocalization of BdABK, TOPRO-3 and anti-IBA-1 in primary microglial cell culture. B1R was induced by a pre-treatment with 300 nM BK. About 95 +/- 2% of the primary cell culture showed a positive labeling with anti-IBA-1 confirming cell purity. Data suggest that B1R can be induced in vitro on microglial cells.
###end p 73
###begin p 74
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Rat microglial primary cultured cells were exposed for 24 h to 300 nM BK to increase B<sub>1</sub>R expression</bold>
###xml 254 255 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat microglial primary cultured cells were exposed for 24 h to 300 nM BK to increase B1R expression. Then, they were exposed to TOPRO-3, a specific fluorescent dye for DNA (A), to anti-IBA-1, a specific antibody against microglia (B) and BdABK to stain B1R (C). Colocalization of the three markers is shown in panel D. TOPRO-3 dye is blue (ext: 642 nm/em: 661 nm), anti-IBA-1 dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 31.75 mum. Pictures presented are representative of 4 cultured cells samples from 4 different animals.
###end p 74
###begin title 75
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R colocalized on sensory C fibers in thoracic spinal cord
###end title 75
###begin p 76
###xml 7 9 7 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 138 139 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 113 117 <span type="species:ncbi:10116">rats</span>
###xml 205 209 <span type="species:ncbi:10116">rats</span>
Figure 11 shows the colocalization of BdABK, anti-TRPV1 and anti-CGRP in the thoracic spinal cord of STZ-treated rats. Data suggest that B1R and TRPV1 are co- localized on sensory C fibers in STZ-diabetic rats.
###end p 76
###begin p 77
###xml 0 94 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">STZ-treated spinal cord was exposed to anti-CGRP, a selective antibody of sensory C fibers (A)</bold>
###xml 175 176 175 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 535 538 <span type="species:ncbi:10116">rat</span>
STZ-treated spinal cord was exposed to anti-CGRP, a selective antibody of sensory C fibers (A). TRPV1 was labeled with anti-TRPV1 another marker of sensory C fibers (B). The B1R was stained with the selective fluorescent agonist, BdABK (C). Colocalization of the three markers is shown in panel D. Anti-CGRP dye is blue (ext: 650 nm/em: 680 nm), anti-TRPV1 dye is red (ext: 550 nm/em: 570 nm), and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 19.21 mum. Pictures presented are representative of a minimum of 4 sections per rat from 4 different animals.
###end p 77
###begin title 78
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R colocalized on astrocytes in thoracic spinal cord
###end title 78
###begin p 79
###xml 7 9 7 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12</xref>
###xml 117 118 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 92 96 <span type="species:ncbi:10116">rats</span>
###xml 178 182 <span type="species:ncbi:10116">rats</span>
Figure 12 shows the colocalization of BdABK and anti-GFAP in the spinal cord of STZ-treated rats. Data suggest that B1R is also present on spinal astrocyte cells in STZ-diabetic rats.
###end p 79
###begin p 80
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">STZ-treated spinal cord was exposed to anti-GFAP, a specific antibody against astrocytes (A) and to BdABK (B)</bold>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 361 364 <span type="species:ncbi:10116">rat</span>
STZ-treated spinal cord was exposed to anti-GFAP, a specific antibody against astrocytes (A) and to BdABK (B). Colocalization between B1R and the astrocytes is shown in panel C. Anti-GFAP dye is red (ext: 550 nm/em: 570 nm) and BdABK dye is green (ext: 505 nm/em: 515 nm). Scale bar = 7.27 mum. Pictures presented are representative of a minimum 4 sections per rat from 4 different animals.
###end p 80
###begin title 81
Discussion
###end title 81
###begin p 82
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 183 184 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 356 357 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 296 300 <span type="species:ncbi:10116">rats</span>
###xml 442 446 <span type="species:ncbi:10116">rats</span>
This study is using a newly developed selective and high affinity fluorescent ligand enabling the cellular localization of B1R on unfixed tissue. It provides the first evidence that B1R is localized on microglial cells, astrocytes and sensory C fibers in the thoracic spinal cord of STZ-diabetic rats. This study also highlights the early upregulation of B1R (mRNA and binding sites) in the thoracic spinal cord of hyperglycaemic STZ-treated rats.
###end p 82
###begin title 83
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Diabetes induces B1R expression
###end title 83
###begin p 84
###xml 120 121 120 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 199 200 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 441 442 441 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 736 738 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 766 767 762 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 770 771 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 772 773 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 774 776 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 880 881 876 877 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 884 885 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 886 887 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 888 890 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 891 893 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 13 17 <span type="species:ncbi:10116">rats</span>
###xml 246 250 <span type="species:ncbi:10116">rats</span>
###xml 552 556 <span type="species:ncbi:10116">rats</span>
###xml 651 655 <span type="species:ncbi:10116">rats</span>
STZ-diabetic rats provide an accessible model for studying the expression, the pharmacology and physiopathology of the B1R in the central nervous system. Pharmacological data showed that functional B1R was expressed in spinal cord of STZ-treated rats; its spinal activation led to sympathetically mediated increases of blood pressure and heart rate [53] and to thermal hyperalgesia [9]. Further autoradiographic and functional evidence for B1R induction was demonstrated in the lung [54], spinal cord [33], retina [6,55] and brain [56] of STZ-diabetic rats. However, this is the first report on mRNA expression in thoracic spinal cord of STZ-diabetic rats by qPCR. Hyperglycaemia associated with type 1 diabetes can activate NF-kappaB [57] which is known to induce B1R [2,3,58]. Moreover, oxidative stress associated with diabetes was reported to be involved in the induction of B1R [6,7,29,59].
###end p 84
###begin title 85
###xml 2 7 2 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#945;</sup>
###xml 23 24 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 45 46 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
[Nalpha-Bodipy]-des-Arg9-BK selectivity for B1R
###end title 85
###begin p 86
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 100 101 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 158 161 158 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 200 201 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 217 220 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 233 235 233 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 255 258 255 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 350 351 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 430 433 428 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 464 465 460 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 512 513 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 531 532 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 539 542 535 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 586 587 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 611 614 605 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 649 652 641 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 694 695 686 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 315 319 <span type="species:ncbi:10116">rats</span>
Experiments by autoradiography confirm that BdABK is highly selective for B1R and does not bind to B2R. Indeed, BdABK failed to displace the B2R radioligand [125I]-HPP-Hoe-140 while it displaced the B1R radioligand, [125I]-HPP-desArg10-Hoe 140, with an IC50 of 5.3 +/- 0.1 nM in thoracic spinal cord of STZ-treated rats. Results also evidenced that B2R binding sites were displaced by the selective antagonist, Hoe 140, with an IC50 value of 1.3 +/- 0.1 nM while B1R binding sites were displaced by the natural B1R agonist, des-Arg9-BK (IC50 = 19 +/- 0.2 nM) and by R-715, a selective B1R peptide antagonist (IC50 = 4.3 +/- 0.2 nM). Comparison of IC50 values suggests that the affinity of the B1R agonist is increased by the addition of the Bodipy molecule. The stabilization of the N-terminus part of the peptide may contribute to prevent its degradation.
###end p 86
###begin p 87
###xml 163 166 162 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 208 209 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 535 536 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 602 603 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 702 703 701 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 470 474 <span type="species:ncbi:10116">rats</span>
The reason for using 50 muM BdABK was based on preliminary study. The concentration of fluorescent probe needed to get a consistent labeling was higher than the IC50 value most likely because BdABK binds to B1R non-covalently and can be eliminated during the washout period of tissue sections. Signal amplification with radioactivity is also expected to be greater than that achieved with a fluorescent probe. BdABK showed no labeling in thoracic spinal cord of control rats which is in accordance with the inducible character of the B1R and its virtual absence in healthy tissues. The elimination of B1R labeling with BdABK after co-incubation with R-715 or SSR240612 confirms the specificity of the B1R fluorescent ligand.
###end p 87
###begin p 88
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 179 180 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 526 527 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 394 398 <span type="species:ncbi:10116">rats</span>
###xml 559 563 <span type="species:ncbi:10116">rats</span>
Interestingly, BdABK maintained its biological activity as B1R agonist in vivo. Data obtained on the Hargreaves test revealed that BdABK was only slightly less potent than des-Arg9-BK to cause thermal hyperalgesia upon peripheral administration. This is consistent with the transient thermal hyperalgesia previously reported in the tail-flick test after intrathecal injection of des-Arg9-BK in rats made diabetics with STZ 24 h earlier [9]. Likewise, Gabra and Sirois [24] showed that intraperitoneal administration of des-Arg9-BK (400 mug/kg) in STZ-treated rats significantly reduced the paw withdraw threshold in the hot plate and tail-flick test.
###end p 88
###begin title 89
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Localization of B1R
###end title 89
###begin title 90
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R on microglial cells
###end title 90
###begin p 91
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 257 258 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 306 308 306 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 441 443 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 469 470 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 510 511 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 89 92 <span type="species:ncbi:10116">rat</span>
###xml 270 273 <span type="species:ncbi:10116">rat</span>
Previous work by Noda and coworkers [50,51] showed that B1R can be expressed in cultured rat microglia exposed to BK. We confirmed this result by using our fluorescent ligand in the same condition, thus providing additional evidence of its ability to bind B1R in a pure rat microglia model. BK acting via B2 receptors induces elevation of intracellular calcium leading to the phosphorylation and activation of NF-kappaB by protein kinase C [60]. NF-kappaB upregulates B1R upon binding to its nuclear promoter [2].
###end p 91
###begin p 92
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 498 499 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 630 631 630 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 711 712 711 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 822 823 822 823 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 913 914 913 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 929 930 929 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 957 958 957 958 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 84 87 <span type="species:ncbi:10116">rat</span>
###xml 446 449 <span type="species:ncbi:10116">rat</span>
###xml 969 973 <span type="species:ncbi:10090">mice</span>
A recent study has demonstrated that B1R is involved in microglial migration toward rat brain lesion sites [61]. The presence of B1R on spinal microglial cells is in keeping with a recent study suggesting that activated dorsal horn microglia is a crucial component of STZ-induced tactile allodynia, mediated in part, by extracellular signal-regulated protein kinase signaling [62]. Importantly, the development of tactile and cold allodynia in a rat model of insulin-resistance was blocked by the B1R antagonist SSR240612 [28] and by two antioxidants (N-acetyl-L-cysteine and alpha-lipoic acid) known to prevent the induction of B1R [7,29]. Taken together, these results suggest a critical role for microglial B1R in generation of tactile allodynia, a manifestation of pain polyneuropathy. It is possible that microglial B1R is also involved in STZ-induced thermal hyperalgesia as this response was abolished by B1R antagonists [5,24,27] and was absent in B1R knockout mice treated with STZ [26].
###end p 92
###begin title 93
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R on astrocytes
###end title 93
###begin p 94
###xml 106 107 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 125 129 <span type="species:ncbi:10116">rats</span>
In addition, the present study provides the first evidence that thoracic spinal cord astrocytes bear the B1R in STZ-diabetic rats. Astrocyte B1R may represent another target for neuropathic or chronic pain. Emerging evidence suggests a critical role for astrocytes in the passage from acute to chronic and neuropathic pain. It seems that intracellular calcium level oscillation in astrocytes could spread through astrocytal network and thereby facilitate the formation of new synapses. These new synapses could establish neuronal contacts for maintaining and spreading pain sensation [63]. Moreover, astrocytes are known to release various inflammatory mediators that promote neuroimmune activation and can sensitize primary afferent sensory neurons contributing to development of neuropathic pain [64].
###end p 94
###begin title 95
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
B1R on sensory C fibers
###end title 95
###begin p 96
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 166 167 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 255 256 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 337 338 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 995 996 995 996 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1109 1110 1109 1110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1230 1231 1230 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 207 210 <span type="species:ncbi:10116">rat</span>
###xml 293 297 <span type="species:ncbi:10116">rats</span>
###xml 1163 1167 <span type="species:ncbi:10116">rats</span>
Immunohistochemical data showed the presence of B1R in DRG and superficial laminae of spinal cord dorsal horn [30-32]. Those studies suggested a basal expression of B1R in primary sensory C fibers of normal rat. This is consistent with the expression of B1R in sensory C fibers of STZ-treated rats as revealed by the co-localization of B1R, CGRP and TRPV1. Horowitz [65] described the crucial role of small A-delta and C fibers in generation of diabetic polyneuropathy and their sensitivity to hyperglycaemia. Ueda's studies [66,67] support the hypothesis that the generation of neuropathic pain is related to alterations in gene and protein expression in primary sensory neurons which could contribute to demyelination of A-delta fibers through the down-regulation of myelin protein such as MBP, MPZ and PMP22. Demyelinated A-delta fibers sprout and synapse with A-beta fibers resulting in the enhancement of pro-nociceptive neurotransmitter release which generated allodynia. The presence of B1R on sensory C fibers is in agreement with an earlier pharmacological study that showed that the stimulation of B1R with an agonist in the spinal cord of STZ-diabetic rats provokes thermal hyperalgesia via the release of substance P [9].
###end p 96
###begin title 97
###xml 7 8 7 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 32 36 <span type="species:ncbi:10116">rats</span>
Basal B1R expression in control rats
###end title 97
###begin p 98
###xml 62 63 62 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 200 201 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 354 355 354 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 423 424 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 537 538 537 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 800 801 800 801 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 932 933 932 933 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 983 984 983 984 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1013 1014 1013 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1137 1138 1137 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 75 79 <span type="species:ncbi:10116">rats</span>
###xml 307 311 <span type="species:ncbi:10116">rats</span>
###xml 384 388 <span type="species:ncbi:10116">rats</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
###xml 995 999 <span type="species:ncbi:10090">mice</span>
###xml 1214 1218 <span type="species:ncbi:10090">mice</span>
Authors failed to observe specific fluorescent labelling for B1R in normal rats which is rather consistent with the negligible level of B1R mRNA and binding sites. Moreover, intrathecal injection of B1R agonists or antagonists failed to cause behavioural, cardiovascular or nociceptive responses in control rats, suggesting that the basal expression of B1R is not functional in naive rats [9,53]. Thus the function of the B1R detected by immunohistochemistry in the spinal cord of rodents and human remains elusive. It is feasible that B1R in control animals is uncoupled to G protein as demonstrated for other G-protein-coupled receptors [68,69]. Although it is possible that the immunological approach is more sensitive, we have evidence (unpublished data) showing that the commercially available B1R antibodies (M-19) from SantaCruz Biotechnologies (Santa Cruz, CA, USA) are not specific for immunohistochemical detection since B1R labeling persists in spinal cord isolated from B1R knockout mice. The latter B1R antibodies remain however suitable for Western blot analysis, suggesting that immunohistochemical studies reported with B1R antibodies remain to be validated with the appropriate controls in mutant mice.
###end p 98
###begin title 99
Conclusion
###end title 99
###begin p 100
###xml 23 24 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 53 54 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 66 69 62 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 315 316 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 566 567 560 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 620 621 614 615 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 100 103 <span type="species:ncbi:10116">rat</span>
###xml 255 259 <span type="species:ncbi:10116">rats</span>
###xml 454 458 <span type="species:ncbi:10116">rats</span>
[Nalpha-Bodipy]-des-Arg9-BK was found selective for B1R with an IC50 value of 5.3 +/- 0.1 nM in the rat spinal cord. Furthermore, BdABK maintains its biological activity as agonist as evidenced by its ability to induce thermal hyperalgesia in STZ-treated rats. This new fluorescent ligand enabled the detection of B1R in primary microglial cell culture and on microglial cells, astrocytes and sensory C fibers in the thoracic spinal cord of STZ-diabetic rats. Because all these cells have been implicated in neuropathic pain, the induction and up-regulation of the B1R on these elements consolidate the idea that kinin B1R is an important target for drug development in pain processes.
###end p 100
###begin title 101
List of abbreviations
###end title 101
###begin p 102
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 12 14 12 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 125 126 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 136 142 <span type="species:ncbi:9913">bovine</span>
B1R: kinin B1 receptor; STZ: streptozotocin; qPCR: quantitative real-time PCR; BK: Bradykinin; BdABK: [Nalpha-Bodipy]-des-Arg9-BK; BSA: bovine serum albumin; anti-IBA-1: anti-Ionized calcium binding adapter molecule 1; anti-GFAP: anti-Glial fibrillary acidic protein; anti-CGRP: anti-calcitonin-gene-related peptide; anti-TRPV1: anti-transient receptor potential vanilloid 1.
###end p 102
###begin title 103
Competing interests
###end title 103
###begin p 104
The authors declare that they have no competing interests.
###end p 104
###begin title 105
Authors' contributions
###end title 105
###begin p 106
###xml 198 207 198 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
ST performed animal treatments, Hargreaves test, real-time PCR analysis, confocal microscopy experiments and draft the manuscript. PTT helped designed the confocal microscopy protocol. DL performed in vitro microglia experiments. JS made cryostat tissue sections and autoradiography experiments. PG synthesized the fluorescent agonist. RC designed the study and revised the manuscript.
###end p 106
###begin title 107
Acknowledgements
###end title 107
###begin p 108
This work was supported by Grant-in-aids from the Canadian Diabetes Association (OG-3-07-2428-RC) and Canadian Institutes of Health Research (MOP-79471). S.T. holds a Studentship from the FRSQ (Fonds de la Recherche en Sante du Quebec). Authors acknowledge Ms Julie Desroches and Dr Pierre Beaulieu for giving us access to the Hargreaves Apparatus and to Mr Michel Lauzon for his expert assistance in confocal microscopy.
###end p 108
###begin article-title 109
Bradykinin receptors and their antagonists
###end article-title 109
###begin article-title 110
International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences
###end article-title 110
###begin article-title 111
Kinin receptors
###end article-title 111
###begin article-title 112
###xml 64 69 <span type="species:ncbi:9606">human</span>
Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects
###end article-title 112
###begin article-title 113
Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus
###end article-title 113
###begin article-title 114
###xml 56 60 <span type="species:ncbi:10116">rats</span>
Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors
###end article-title 114
###begin article-title 115
###xml 110 113 <span type="species:ncbi:10116">rat</span>
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-Acetyl-l-Cysteine and ramipril in a rat model of insulin resistance
###end article-title 115
###begin article-title 116
Kinins in pain and inflammation
###end article-title 116
###begin article-title 117
Kinin receptors in pain and inflammation
###end article-title 117
###begin article-title 118
Targeting kinin receptors for the treatment of neurological diseases
###end article-title 118
###begin article-title 119
###xml 146 150 <span type="species:ncbi:10090">mice</span>
Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice
###end article-title 119
###begin article-title 120
###xml 45 49 <span type="species:ncbi:10090">mice</span>
The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level
###end article-title 120
###begin article-title 121
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors
###end article-title 121
###begin article-title 122
###xml 120 123 <span type="species:ncbi:10116">rat</span>
Induction of bradykinin B1 receptors in vivo in a model of ultra-violet irradiation-induced thermal hyperalgesia in the rat
###end article-title 122
###begin article-title 123
###xml 111 114 <span type="species:ncbi:10116">rat</span>
The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat
###end article-title 123
###begin article-title 124
###xml 104 108 <span type="species:ncbi:10090">mice</span>
The role of kinin B1 receptors in the nociception produced by peripheral protein kinase C activation in mice
###end article-title 124
###begin article-title 125
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
Evidence for participation of B1 and B2 kinin receptors in formalin-induced nociceptive response in the mouse
###end article-title 125
###begin article-title 126
SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R, 6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization
###end article-title 126
###begin article-title 127
###xml 81 84 <span type="species:ncbi:10116">rat</span>
Spatio-temporal pattern of induction of bradykinin receptors and inflammation in rat dorsal root ganglia after unilateral nerve ligation
###end article-title 127
###begin article-title 128
Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain
###end article-title 128
###begin article-title 129
Plasticity in the expression of bradykinin binding sites in sensory neurons after mechanical nerve injury
###end article-title 129
###begin article-title 130
###xml 39 42 <span type="species:ncbi:10116">rat</span>
Role of kinin B1 and B2 receptors in a rat model of neuropathic pain
###end article-title 130
###begin article-title 131
###xml 138 142 <span type="species:ncbi:10116">rats</span>
Peripheral kinin B(1) and B(2) receptor-operated mechanisms are implicated in neuropathic nociception induced by spinal nerve ligation in rats
###end article-title 131
###begin article-title 132
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Role of bradykinin B(1) receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice
###end article-title 132
###begin article-title 133
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor
###end article-title 133
###begin article-title 134
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice
###end article-title 134
###begin article-title 135
###xml 120 124 <span type="species:ncbi:10116">rats</span>
Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/Worchester rats: efficacy of a selective bradykinin B1 receptor antagonist
###end article-title 135
###begin article-title 136
###xml 98 101 <span type="species:ncbi:10116">rat</span>
The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance
###end article-title 136
###begin article-title 137
###xml 124 127 <span type="species:ncbi:10116">rat</span>
Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance
###end article-title 137
###begin article-title 138
###xml 128 132 <span type="species:ncbi:10116">rats</span>
The expression of bradykinin B(1) receptors on primary sensory neurones that give rise to small caliber sciatic nerve fibers in rats
###end article-title 138
###begin article-title 139
###xml 67 73 <span type="species:ncbi:9606">humans</span>
###xml 78 82 <span type="species:ncbi:10116">rats</span>
Basal expression of bradykinin B(1) receptor in the spinal cord in humans and rats
###end article-title 139
###begin article-title 140
###xml 58 61 <span type="species:ncbi:10116">rat</span>
Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system
###end article-title 140
###begin article-title 141
###xml 79 82 <span type="species:ncbi:10116">rat</span>
Expression of kinin B1 receptors in the spinal cord of streptozotocin-diabetic rat
###end article-title 141
###begin article-title 142
Synthesis of a biologically active fluorescent probe for labelling of neurotensin receptors
###end article-title 142
###begin article-title 143
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 49 52 <span type="species:ncbi:10116">rat</span>
Internalization and trafficking of the human and rat growth hormone-releasing hormone receptor
###end article-title 143
###begin article-title 144
Immunofluorescence studies on formalin-fixed and paraffin-embedded material
###end article-title 144
###begin article-title 145
Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma -dependent pathway
###end article-title 145
###begin article-title 146
Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS
###end article-title 146
###begin article-title 147
Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease
###end article-title 147
###begin article-title 148
Transient coexpression of nestin, GFAP, and vascular endothelial growth factor in mature reactive astroglia following neural grafting or brain wounds
###end article-title 148
###begin article-title 149
Cell adhesion molecule L1 modulates nerve-growth-factor-induced CGRP-IR fiber sprouting
###end article-title 149
###begin article-title 150
Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough
###end article-title 150
###begin article-title 151
Identification of an axotomy-induced glycosylated protein, AIGP1, possibly involved in cell death triggered by endoplasmic reticulum-Golgi stress
###end article-title 151
###begin article-title 152
Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation
###end article-title 152
###begin article-title 153
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
###end article-title 153
###begin article-title 154
###xml 35 40 <span type="species:ncbi:9606">human</span>
Preparation of iodine-131 labelled human growth hormone of high specific activity
###end article-title 154
###begin article-title 155
Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies
###end article-title 155
###begin article-title 156
Calibration of 125I-polymer standards with 125I-brain paste standards for use in quantitative receptor autoradiography
###end article-title 156
###begin article-title 157
###xml 75 78 <span type="species:ncbi:10116">rat</span>
Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue
###end article-title 157
###begin article-title 158
Expression and function of bradykinin receptors in microglia
###end article-title 158
###begin article-title 159
###xml 28 31 <span type="species:ncbi:10116">rat</span>
Kinin receptors in cultured rat microglia
###end article-title 159
###begin article-title 160
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
###end article-title 160
###begin article-title 161
###xml 161 165 <span type="species:ncbi:10116">rats</span>
Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats
###end article-title 161
###begin article-title 162
###xml 74 77 <span type="species:ncbi:10116">rat</span>
Up-regulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence
###end article-title 162
###begin article-title 163
###xml 96 99 <span type="species:ncbi:10116">rat</span>
Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat
###end article-title 163
###begin article-title 164
###xml 56 59 <span type="species:ncbi:10116">rat</span>
Expression and distribution of kinin B1 receptor in the rat brain and alterations induced by diabetes in the model of streptozotocin
###end article-title 164
###begin article-title 165
Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells
###end article-title 165
###begin article-title 166
###xml 155 160 <span type="species:ncbi:9606">human</span>
The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts
###end article-title 166
###begin article-title 167
###xml 56 59 <span type="species:ncbi:10116">rat</span>
Increases of spinal kinin receptor binding sites in two rat models of insulin resistance
###end article-title 167
###begin article-title 168
###xml 122 127 <span type="species:ncbi:9606">human</span>
Role of the Rho GTPase in bradykinin-stimulated nuclear factor-kappaB activation and IL-1beta gene expression in cultured human epithelial cells
###end article-title 168
###begin article-title 169
Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca2+ influx via reverse-mode activity of the Na+/Ca2+ exchanger
###end article-title 169
###begin article-title 170
Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling
###end article-title 170
###begin article-title 171
Could chronic pain and spread of pain sensation be induced and maintained by glial activation?
###end article-title 171
###begin article-title 172
Immune and inflammatory mechanisms in neuropathic pain
###end article-title 172
###begin article-title 173
Recent clinical advances in diabetic polyneuropathy
###end article-title 173
###begin article-title 174
Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms
###end article-title 174
###begin article-title 175
Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination
###end article-title 175
###begin article-title 176
beta-arrestin: A protein that regulates beta-adrenergic receptor function
###end article-title 176
###begin article-title 177
Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases
###end article-title 177

